Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.2K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

274
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
274
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

538
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
538
Drug Regulation01:25

Drug Regulation

2.6K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.6K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.2K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.2K
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

426
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
426

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adherence to legislation and recommendations to publicly post protocols and results of post-authorisation studies registered with European Medicines Agency: cross sectional study.

BMJ (Clinical research ed.)·2026
Same author

Availability of consent forms in ClinicalTrials.gov for industry-sponsored trials.

Health affairs scholar·2025
Same author

How to use the regulatory data from Health Canada for secondary analyses on new drugs, biologics and vaccines.

BMJ evidence-based medicine·2023
Same author

How the case counting window affected vaccine efficacy calculations in randomized trials of COVID-19 vaccines.

Journal of evaluation in clinical practice·2023
Same author

Definition and rationale for placebo composition: Cross-sectional analysis of randomized trials and protocols published in high-impact medical journals.

Clinical trials (London, England)·2023
Same author

Sources of bias in observational studies of covid-19 vaccine effectiveness.

Journal of evaluation in clinical practice·2023

Related Experiment Video

Updated: Dec 27, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K

Statins for primary prevention: what is the regulator's role?

Tom Jefferson1, Maryanne Demasi2, Peter Doshi3

  • 1Nordic Cochrane Centre, Rigshospitalet Dept. 7811, Copenhagen, Denmark tj@cochrane.dk.

BMJ Evidence-Based Medicine
|February 28, 2020
PubMed
Summary

Drug regulators approved statins for cardiovascular disease prevention, but data access is fragmented. A review found no central archive for statin approval data, hindering public and researcher access.

Keywords:
clinical trialscoronary heart diseaseepidemiologyhealth policyischaemic heart disease

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.0K

Related Experiment Videos

Last Updated: Dec 27, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.0K

Area of Science:

  • Pharmacology
  • Regulatory Science
  • Cardiovascular Medicine

Background:

  • Statins are widely approved for cardiovascular disease (CVD) prevention.
  • Their use in primary prevention remains controversial, with ongoing debate about benefit-risk balance.
  • Drug regulatory agencies have not publicly addressed this debate.

Purpose of the Study:

  • To investigate European drug regulators' decision-making processes for statin approvals.
  • To request and examine the data underpinning statin licensing.

Main Methods:

  • Analysis of regulatory procedures across European countries.
  • Inquiries regarding data accessibility and archival practices for statin approvals.

Main Results:

  • European drug regulation for statins is fragmented; many nations license drugs without independent data analysis.
  • No centralized, accessible archive exists for statin approval information or trial data.
  • Current system lacks transparency and accessibility for the public and researchers.

Conclusions:

  • The fragmented regulatory system for statins is unsustainable.
  • Improved data accessibility and centralized archiving are needed for public trust and scientific advancement.
  • Regulatory bodies must enhance transparency in drug approval processes.